TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06768632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: single-dose of test formulation+single-dose of reference formulation
Description: Eltrombopag Tablets is a small molecule non peptide thrombopoietin receptor agonist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: single-dose of reference formulation+single-dose of test formulation
Description: Eltrombopag Tablets is a small molecule non peptide thrombopoietin receptor agonist.
Study: NCT04318028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 7 Tesla Magnetic Resonance Imaging
Description: Undergo 7 Tesla MRI
Study: NCT01516775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clear fluid ingestion
Description: drinking of clear fluid in preoperative period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clear fluid ingestion
Description: drinking of clear fluid in preoperative period
Study: NCT03114371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: The study drug is oxytocin in intra-nasal administration, Syntocinon®, reconditioned as a placebo-like spray. The dosage administered will be 8 International Unit, ie 1 spray (4 International Unit per spray) in each nostril per day for the first 12 weeks, in 3 and 6 years old patients. The dosage administered will be 16 International Unit or 2 sprays in each nostril per day for the first 12 weeks, in 3 to 6 years old patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo should be used as a spray, similar to that of the oxytocin. The dosage administered will be 1 spray in each nostril per day for the first 12 weeks in 3 to 6 years old patients. The dosage administered will be 2 sprays in each nostril per day for the first 12 weeks, in 7 to 12 years old patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Each patient will receive oxytocin in open label (Syntocinon® not reconditioned) from week 13 to week 24 according to the same dosages.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: Each patient will receive oxytocin in open label (Syntocinon® not reconditioned) from week 13 to week 24 according to the same dosages.
Study: NCT00673062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900538
Description: (4X50mg Capsules)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine
Description: Encapsulated pseudoephedrine (2X30 mg immediate release tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Placebo
Study: NCT00278538

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Autologous hematopoietic stem cell transplantation
Study: NCT01165073

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Osmolite and B.C.A.A.
Description: Feeding inserted into enteral tubes

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal oral intake & supplementation if necessary
Description: Enteral nutrition
Study: NCT03993236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Rosuvastatin/Ezetimibe 10
Description: * Rosuvastatin/Ezetimibe 10/10mg~* orally administered once daily for 90 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Rosuvastatin 20mg
Description: * Rosuvastatin 20mg~* orally administered once daily for 90 days
Study: NCT00765297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fall related movement (stumble) detector
Description: movement pattern (gait,balance) of young subjects recovery of a stumble in young subjects

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fall related movement characteristic (stumble) detector
Description: age related gait changes influencing movement pattern different pattern to recover from a trip
Study: NCT02219581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard multimodal pain management regimen
Description: The standard multimodal postoperative pain management regimen typically used for total knee arthroplasty consists of the following:~Preoperative:~* Decadron: 10 or 20mg IV x 1 2 doses, 8 hours apart (if randomized to study group)~Intraoperative:~* Ropivacaine: Given intraoperatively. Capsule, subcutaneous tissue/skin. Administered in standard fashion. (300mg)~* Toradol: 30mg q 6hr for 6 total doses. 1st dose given intraoperatively at incision. The dose is 15 mg for older patients or if creatinine clearance (CrCl) is low.~Postoperative~* Tylenol: 1000mg po q 8hr (scheduled)~* Oxycodone: 5mg or 10mg q 3-4hr prn pain, If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid~* IV Morphine (or Dilaudid): 1 or 2 mg q 2hr prn breakthrough pain~* Morphine patient-controlled analgesia (PCA): only for failure of the above~* Morphine Sulfate (MS) Contin: Use as backup prn pain
Study: NCT04755270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR Glasses
Description: techniques of hypnofertility and VR glasses
Study: NCT01364922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocodone/acetaminophen extended release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocodone/acetaminophen extended release

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02359643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: This study was conduct to investigate the role of high dose aspirin in acute stage of KD via a multi-center randomized control trail, and we plan to achieve the followings in the coming 4 years:~1. Enroll 300 KD patients from multiple medical centers of Taiwan and China in 4 years. Randomize group patients as group 1: with high dose aspirin (more than 30/mg/kd/day) until fever subsided and shift to low dose aspirin (3-5mg/kg/day, N=150); and group 2: without high dose aspirin during acute febrile stage, only use low dose aspirin (N=150).~2. Compare data including fever days, admission duration, laboratory data (CBC/DC, GOT/GPT, BUN/Cr, Alb, ESR, CRP, 2D echo), IVIG treatment response and CAL formation rate (followed at least 1 year).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: This study was conduct to investigate the role of high dose aspirin in acute stage of KD via a multi-center randomized control trail, and we plan to achieve the followings in the coming 4 years:~1. Enroll 300 KD patients from multiple medical centers of Taiwan and China in 4 years. Randomize group patients as group 1: with high dose aspirin (more than 30/mg/kd/day) until fever subsided and shift to low dose aspirin (3-5mg/kg/day, N=150); and group 2: without high dose aspirin during acute febrile stage, only use low dose aspirin (N=150).~2. Compare data including fever days, admission duration, laboratory data (CBC/DC, GOT/GPT, BUN/Cr, Alb, ESR, CRP, 2D echo), IVIG treatment response and CAL formation rate (followed at least 1 year).
Study: NCT02018445

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Posterolateral Fusion
Study: NCT00647101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: Latanoprost 0.005% drops: 1 drop in the diseased eye(s) in the evening for 3 months
Study: NCT00651235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan and Atenolol or Propranolol
Description: 50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children.~Losartan is 100 mg/day for adult and 50 mg/day for children.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol or Propranolol
Description: The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
Study: NCT01988363

Intervention type: PROCEDURE
Group type: OTHER
Intervention: GON injection at C2 location
Description: GON will be identified at the novel, proximal C2 location on the symptomatic side via ultrasound guidance. Prior to injection, an independent examiner will perform a sensory exam of the involved dermatome. A 25 gauge spinal needle will be inserted into the symptomatic side after locating the GON via ultrasound at the C2 level. Subjects will be injected with treatment medication. Thirty minutes after injection, an independent examiner will test for anesthesia over the desired dermatome. VAS will be assessed pre-injection, 30 post-injection, 2 weeks post-injection and 1 month post-injection. The 2 week and 1 month assessments will be conducted by telephone.
Study: NCT01595243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone consultations about psychoeducation program
Description: experimental group will receive seven instances of telephone follow-up or face-to-face education (the day before discharge and during the first, second, third, fourth, sixth, and eighth weeks after discharge).
Study: NCT00299000

Intervention type: DRUG
Group type: OTHER
Intervention: Naglazyme
Description: Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution

Intervention type: DRUG
Group type: OTHER
Intervention: Naglazyme
Description: Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution
Study: NCT02412501

Intervention type: DEVICE
Group type: OTHER
Intervention: Resolute Onyx Stent - 2.0 mm
Description: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent
Study: NCT02887469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% hypertonic saline
Description: The same as above

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% hypertonic saline
Description: The same as above
Study: NCT04092179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Enasidenib is a drug that blocks a protein called isocitrate dehydrogenase (IDH) 2 from working. The family of IDH proteins have been indicated in the development of leukemia. By blocking IDH2, enasidenib may help stop cancer cells from growing. It is believed that the drug may be more useful in patients with a change (mutation) in their IDH 2 protein. The IDH2 gene (substances in the body that contain instructions for the proper development and function of cells) makes IDH2 proteins. As such, only patients with IDH 2 mutated gene are eligible for this study. Enasidenib is currently approved for the treatment of IDH2 mutated AML.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is a drug that blocks a protein called B-cell lymphoma (BCL2) protein from working. BCL2 is a protein that helps control whether a cell lives or dies and is thought to help cancer cells to live. Blocking BCL2 is believed to help kill cancer cells. Venetoclax is currently approved for the treatment of type of blood cancer called chronic lymphocytic leukemia (CLL) who have received prior treatment.
Study: NCT03755635

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: The WHO multimodal hand hygiene strategy
Description: Comprises five essential elements; system change-availability of alcohol-based hand rub at the point of care and/ or access to safe continuous water supply and soap and towels; training and education of healthcare professionals; monitoring of hand hygiene practices and performance feedback; reminders in the workplace; and the creation of a hand hygiene safety culture with the participation of both individual healthcare workers and senior hospital managers.
Study: NCT01437150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomical locking plate
Description: This is a new fixation treat for acetabular posterior wall fracture.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomical locking plate
Description: This is a new fixation treat for acetabular posterior wall fracture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Reconstructive Plate
Description: Reconstructive plate was used very common in treatment of acetabular fracture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Reconstructive Plate
Description: Reconstructive plate was used very common in treatment of acetabular fracture.
Study: NCT03717402

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention Participants
Description: Patients with advances cancer using opioids for chronic pain will be enrolled and asked to use the STAMP cancer pain management app for 4 weeks.
Study: NCT02244801

Intervention type: DRUG
Group type: OTHER
Intervention: darTreg infusion
Description: The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients. sBc production for darTreg manufacturing for the second subject in each cohort may be initiated but the second subject may not undergo leukapheresis until the safety review is complete.~Once the last subject in the first cohort reaches week 4 post-infusion, the DSMB will conduct a thorough review of all available data to make a determination about proceeding with additional patients at the lower dose or proceeding to the second dosing cohort. sBc production for darTreg manufacturing for the subsequent subject may be initiated but the patient may not undergo leukapheresis until the DSMB( Data Safety and Monitoring Board ) has approved enrollment of subsequent subjects.

Intervention type: DRUG
Group type: OTHER
Intervention: darTreg infusion
Description: The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients. sBc production for darTreg manufacturing for the second subject in each cohort may be initiated but the second subject may not undergo leukapheresis until the safety review is complete.~Once the last subject in the first cohort reaches week 4 post-infusion, the DSMB will conduct a thorough review of all available data to make a determination about proceeding with additional patients at the lower dose or proceeding to the second dosing cohort. sBc production for darTreg manufacturing for the subsequent subject may be initiated but the patient may not undergo leukapheresis until the DSMB( Data Safety and Monitoring Board ) has approved enrollment of subsequent subjects.
Study: NCT01139190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL3100
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Oral administration
Study: NCT03305874

Intervention type: OTHER
Intervention: Exposure to CBCIN risk score
Description: The computer-based contrast induced nephropathy (CBCIN) risk score and associated standard hydration strategy will be displayed on a monitor in front of the treating interventional cardiologist during the entirety of the PCI case. Since this scoring system and hydration strategy are both available in the peer-reviewed literature, clinical use of these data and implementation of a CIN-avoidance strategy is not experimental; however, the display of these data to interventional cardiologists is experimental. Based on exposure to these data, the treating interventional cardiologist may use the information as clinically appropriate (i.e. it is not the basis for clinical decisions).
Study: NCT02816034

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visuo-motor rotation
Description: Participant moves a cursor on a screen by sliding a pen over a digital tablet. Participants perform a center-out movement, aiming to a target that appears over one of a set of eight markers radially distributed. In several block of trials, the mapping of the pen position to the cursor is rotated.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visuo-motor rotation
Description: Participant moves a cursor on a screen by sliding a pen over a digital tablet. Participants perform a center-out movement, aiming to a target that appears over one of a set of eight markers radially distributed. In several block of trials, the mapping of the pen position to the cursor is rotated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visuo-motor rotation
Description: Participant moves a cursor on a screen by sliding a pen over a digital tablet. Participants perform a center-out movement, aiming to a target that appears over one of a set of eight markers radially distributed. In several block of trials, the mapping of the pen position to the cursor is rotated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visuo-motor rotation
Description: Participant moves a cursor on a screen by sliding a pen over a digital tablet. Participants perform a center-out movement, aiming to a target that appears over one of a set of eight markers radially distributed. In several block of trials, the mapping of the pen position to the cursor is rotated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Explicit strategy
Description: Participant is provided with an explicit instruction as to how counteract the effects of the visuo-motor rotation via aiming to a marker adjacent target

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Explicit strategy
Description: Participant is provided with an explicit instruction as to how counteract the effects of the visuo-motor rotation via aiming to a marker adjacent target
Study: NCT03135561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pedometer-plus-email
Description: After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. During the intervention period, patients will receive 8 counselling emails based on behavioural techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pedometer-only
Description: After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. There will be no further interaction during the intervention period unless they fail to upload data, in which case they will be offered technical support.
Study: NCT01023568

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh blade
Description: Intubation with Macintosh blade laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: Intubation with Glidescope laryngoscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Truview PCD
Description: Intubation with Truview PCD laryngoscope.
Study: NCT04402528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral tools integrated within mehealth for ADHD software
Description: Integrated functionality within the mehealth for ADHD software allows parents and teachers/childcare providers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
Study: NCT00668135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil (Levitra, BAY38-9456)
Description: Vardenafil 10 mg orally on demand prior to intercourse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01985620

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Study: NCT03227016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: Topotecan at increasing doses (1x or 2x per day) will be administered in each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan at dose 1.25 mg/m2 will be administered in each cycle.
Study: NCT03924713

Intervention type: BEHAVIORAL
Intervention: Supportive services
Description: Assessment of behavioral, medical, and social needs, development of individual goals and action plan, follow-up to assist and work to ensure identified needs/goals are met. CHWs use their professional judgement to assess how long follow-up is required.

Intervention type: BEHAVIORAL
Intervention: Supportive services
Description: Assessment of behavioral, medical, and social needs, development of individual goals and action plan, follow-up to assist and work to ensure identified needs/goals are met. CHWs use their professional judgement to assess how long follow-up is required.
Study: NCT02219581

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard multimodal pain management regimen
Description: The standard multimodal postoperative pain management regimen typically used for total knee arthroplasty consists of the following:~Preoperative:~* Decadron: 10 or 20mg IV x 1 2 doses, 8 hours apart (if randomized to study group)~Intraoperative:~* Ropivacaine: Given intraoperatively. Capsule, subcutaneous tissue/skin. Administered in standard fashion. (300mg)~* Toradol: 30mg q 6hr for 6 total doses. 1st dose given intraoperatively at incision. The dose is 15 mg for older patients or if creatinine clearance (CrCl) is low.~Postoperative~* Tylenol: 1000mg po q 8hr (scheduled)~* Oxycodone: 5mg or 10mg q 3-4hr prn pain, If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid~* IV Morphine (or Dilaudid): 1 or 2 mg q 2hr prn breakthrough pain~* Morphine patient-controlled analgesia (PCA): only for failure of the above~* Morphine Sulfate (MS) Contin: Use as backup prn pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo arm will receive two doses of saline intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
Study: NCT02738255

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Varnum mouthpiece
Description: An adhesive mouthpiece with a central opening applied during sleep
Study: NCT02300012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgeons knowledge of pre-operative PBIs
Description: Surgeon performing ACL repair will have prior knowledge of patients pre-operative PBIs to inform surgical practice
Study: NCT01105806

Intervention type: BEHAVIORAL
Intervention: (CPR) video and questionnaires
Description: Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)